Table 3.

Baseline demographics between tetrabenazine and olanzapine groups

	Tetrabenazine	Olanzapine	P‐value
N	77	77
% Female	50.0	50.0	1.000
CAG, mean±S.D.	43.14 ± 2.87	43.48 ± 2.85	0.466
Age0 (yrs), mean±S.D.	57.91 ± 10.57	56.30 ± 11.00	0.355
AMO (yrs), mean±S.D.	48.03 ± 10.70	47.47 ± 10.83	0.752
CAP0, mean±S.D.	117.86 ± 17.80	117.45 ± 17.51	0.884
TMS0, mean±S.D.	43.75 ± 18.02	42.78 ± 19.04	0.745
TFC0, mean±S.D.	7.04 ± 3.09	6.96 ± 3.10	0.876
Weight0 (kg), mean±S.D.	74.17 ± 16.41	72.63 ± 17.35	0.573
BMI0 (kg/m2), mean±S.D.	25.64 ± 5.90	25.18 ± 5.23	0.606
Baseline depression score, mean±S.D.	1.62 ± 2.70	2.61 ± 3.50	0.052
Baseline suicidality score, mean±S.D.	0.05 ± 0.28	0.43 ± 1.52	0.035
Baseline aggression score, mean±S.D.	0.62 ± 1.71	1.21 ± 2.07	0.058
Baseline irritability score, mean±S.D.	1.56 ± 2.63	2.70 ± 3.44	0.022
Time between first and second visit (yrs), mean±S.D.	1.09 ± 0.27	1.06 ± 0.23	0.477
Daily dose (mg), mean±S.D.1	60.07 ± 53.84	6.95 ± 5.88	N/A
Prior time on therapy (yrs), mean±S.D.	2.23 ± 2.20	2.16 ± 2.55	0.840
Medication indicated for chorea, %1	100	41.6	N/A

Abbreviations: AMO, age of motor onset; BMI₀, baseline body mass index; CAG: cytosine‐adenine‐guanine; CAP₀: baseline disease burden score calculated age₀ x ([CAG‐30]/6.27); TFC₀: baseline total functional capacity score; TMS₀: baseline total motor score.

¹Statistical significance not calculated.